Common polymorphism responsible for HCV genotype 3 resistance to Sovaldi

Researchers identified a common polymorphism and a rare variant combination in hepatitis C genotype 3 that are responsible for a reduced response to Sovaldi, according to a study published in Gastroenterology.
“Studies on [Sovaldi] ‘resistance’ have been hampered by the extraordinary efficacy of the drug, which has led to very few treatment failures,” Peter A.C. Wing, PhD, from the Queen Mary University of London in the United Kingdom, and colleagues wrote. “Our analysis shows that reduced response to [Sovaldi] may occur if multiple viral polymorphisms are combined.”

Source link

Related posts

Where does your financial advisor’s duty lie?


Targeting the gut to protect the heart


Despite barriers, children with IBD can still succeed in school


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World